OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED)

CAPS Rating: 4 out of 5

Results 1 - 3 of 3

Recs

0
Member Avatar Tophinater (41.27) Submitted: 11/17/2014 2:50:42 PM : Outperform Start Price: $20.12 OMED Score: +7.91

i don't know.

Recs

0
Member Avatar manirg (69.00) Submitted: 1/29/2014 12:07:04 PM : Outperform Start Price: $31.42 OMED Score: -46.30

High Risk but has Hugh Potential--5 to 10x. Backed by Celgene.

Recs

0
Member Avatar 5zillion (< 20) Submitted: 7/24/2013 3:40:08 PM : Outperform Start Price: $23.50 OMED Score: -29.51

Got in on tail end of this IPO and paid on the high end. Have to admit I have been biting my fingernails a little bit on this one. I do believe that with patience this one will pay off. With interest from GSK and Bayer I do believe they will be a good investment in due time.

Results 1 - 3 of 3

Featured Broker Partners


Advertisement